Bristol Myers Squibb (BMY) News Today

Bristol-Myers Squibb Company (NYSE: BMY) saw a mix of pipeline developments, cost initiatives and analyst revisions influencing its share performance today. Although research misses and forecast cuts weighed on sentiment, the launch of a direct-to-patient Eliquis program helped underpin gains.

• Positive Sentiment: Eliquis Direct-to-Patient Discount Program – BMY and Pfizer will sell their blockbuster blood thinner Eliquis at a more-than-40% discount through a new direct-to-consumer service, improving patient access and potentially boosting volume. Eliquis Discount Program
• Neutral Sentiment: New Clinical Trials Launched – The company initiated multiple Phase 2 studies, including a lung cancer therapy, an Alzheimer’s candidate, and KarXT trials in bipolar-I and schizophrenia, expanding its pipeline with longer-term readouts. Lung Cancer Study Alzheimer’s Study KarXT Bipolar-I Study KarXT Schizophrenia Study
• Neutral Sentiment: BofA Keeps ‘Hold’ Rating – Bank of America Securities reaffirmed its hold rating on BMY, suggesting limited upside in the near term. BofA Hold Rating
• Neutral Sentiment: Shares Outpace the Market – BMY stock has outperformed broader indices, reflecting investor focus on its late-stage programs and the new Eliquis initiative. Market Performance
• Negative Sentiment: Psoriasis Trial Halted – BMY terminated its psoriasis study after disappointing efficacy results, raising questions about near-term R&D momentum. Psoriasis Study Termination
• Negative Sentiment: EPS Forecasts Cut – William Blair trimmed BMY’s FY2025 EPS estimate to $6.22 (from $6.77) and its Q2 EPS to $1.03, citing slower growth drivers. William Blair EPS Cuts
• Negative Sentiment: Higher R&D Expenses – A $3.5 billion bispecific antibody collaboration with BioNTech could pressure margins and cash flow amid ramped-up spending. BioNTech Expense Impact

Overall, initiatives to broaden patient access and diversify the pipeline drove BMY shares higher, while study setbacks and downward earnings revisions tempered some of the upside.